Detoxification of oxidative stress in glioma stem cells: Mechanism, clinical relevance, and therapeutic development

Journal of Neuroscience Research

Volumn 92, Issue 11, 2014, Pages 1419-1424

  Kim, Sung Hak ^a   Kwon, Chang Hyuk ^a   Nakano, Ichiro ^a,b  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

Cancer stem cell; Glioblastoma; Glioma stem cell; Oxidative stress; Reactive oxygen species

Indexed keywords

PEROXIREDOXIN 4; REACTIVE OXYGEN METABOLITE; ANTIOXIDANT; PEROXIREDOXIN; PRDX4 PROTEIN, HUMAN;

CANCER GRADING; CANCER GROWTH; CANCER RECURRENCE; CANCER STEM CELL; CARCINOGENESIS; CELL HYPOXIA; CELL PROLIFERATION; CELL SURVIVAL; DETOXIFICATION; GLIOMA STEM CELL; HUMAN; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; ANIMAL; DRUG EFFECTS; DRUG INACTIVATION; GLIOMA; METABOLISM; PATHOLOGY; PHYSIOLOGY;

ANIMALS; ANTIOXIDANTS; GLIOMA; HUMANS; INACTIVATION, METABOLIC; NEOPLASTIC STEM CELLS; OXIDATIVE STRESS; PEROXIREDOXINS; REACTIVE OXYGEN SPECIES;

EID: 84906324132     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.23431     Document Type: Review

References (58)

1. Acharya A, Das I, Chandhok D, Saha T. 2010. Redox regulation in cancer: a double-edged sword with therapeutic potential. Oxid Med Cell Longev 3:23-34.
2. Ayuso-Sacido A, Graham C, Greenfield JP, Boockvar JA. 2006. The duality of epidermal growth factor receptor (EGFR) signaling and neural stem cell phenotype: cell enhancer or cell transformer? Curr Stem Cell Res Ther 1:387-394.
3. Badr CE, Van Hoppe S, Dumbuya H, Tjon-Kon-Fat LA, Tannous BA. 2013. Targeting cancer cells with the natural compound obtusaquinone. JNCI 105:643-653.
4. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW, Bigner DD, Rich JN. 2006. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444:756-760.
5. Bezerra DP, Pessoa C, Moraes MO, Alencar NM, Mesquita RO, Lima MW, Alves AP, Pessoa OD, Chaves JH, Silveira ER, Costa-Lotufo LV. 2008. In vivo growth inhibition of sarcoma 180 by piperlonguminine, an alkaloid amide from the Piper species. J Appl Toxicol 28:599-607.
6. Brennan C, Momota H, Hambardzumyan D, Ozawa T, Tandon A, Pedraza A, Holland E. 2009. Glioblastoma subclasses can be defined by activity among signal transduction pathways and associated genomic alterations. PLoS One 4:e7752.
7. Cabarcas SM, Mathews LA, Farrar WL. 2011. The cancer stem cell niche-there goes the neighborhood? Int J Cancer 129:2315-2327.
8. Cancer Genome Atlas Research Network. 2008. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455:1061-1068.
9. Chang KP, Yu JS, Chien KY, Lee CW, Liang Y, Liao CT, Yen TC, Lee LY, Huang LL, Liu SC, Chang YS, Chi LM. 2011. Identification of PRDX4 and P4HA2 as metastasis-associated proteins in oral cavity squamous cell carcinoma by comparative tissue proteomics of microdissected specimens using iTRAQ technology. J Proteome Res 10:4935-4947.
10. Chen J, Li Y, Yu TS, McKay RM, Burns DK, Kernie SG, Parada LF. 2012. A restricted cell population propagates glioblastoma growth after chemotherapy. Nature 488:522-526.
11. Chen TC, Wang W, Golden EB, Thomas S, Sivakumar W, Hofman FM, Louie SG, Schonthal AH. 2011. Green tea epigallocatechin gallate enhances therapeutic efficacy of temozolomide in orthotopic mouse glioblastoma models. Cancer Lett 302:100-108.
12. Eramo A, Ricci-Vitiani L, Zeuner A, Pallini R, Lotti F, Sette G, Pilozzi E, Larocca LM, Peschle C, De Maria R. 2006. Chemotherapy resistance of glioblastoma stem cells. Cell Death Differ 13:1238-1241.
13. Fang YZ, Yang S, Wu G. 2002. Free radicals, antioxidants, and nutrition. Nutrition 18:872-879.
14. Golovine KV, Makhov PB, Teper E, Kutikov A, Canter D, Uzzo RG, Kolenko VM. 2013. Piperlongumine induces rapid depletion of the androgen receptor in human prostate cancer cells. Prostate 73:23-30.
15. Han SS, Son DJ, Yun H, Kamberos NL, Janz S. 2013. Piperlongumine inhibits proliferation and survival of Burkitt lymphoma in vitro. Leuk Res 37:146-154.
16. Iuchi Y, Okada F, Tsunoda S, Kibe N, Shirasawa N, Ikawa M, Okabe M, Ikeda Y, Fujii J. 2009. Peroxiredoxin 4 knockout results in elevated spermatogenic cell death via oxidative stress. Biochem J 419:149-158.
17. Jacinto FV, Esteller M. 2007. MGMT hypermethylation: a prognostic foe, a predictive friend. DNA Repair 6:1155-1160.
18. Jijiwa M, Demir H, Gupta S, Leung C, Joshi K, Orozco N, Huang T, Yildiz VO, Shibahara I, de Jesus JA, Yong WH, Mischel PS, Fernandez S, Kornblum HI, Nakano I. 2011. CD44v6 regulates growth of brain tumor stem cells partially through the AKT-mediated pathway. PLoS One 6:e24217.
19. Karihtala P, Kauppila S, Soini Y, Arja-Jukkola-Vuorinen A. 2011. Oxidative stress and counteracting mechanisms in hormone receptor positive, triple-negative and basal-like breast carcinomas. BMC Cancer 11:262.
20. Kim TH, Song J, Alcantara Llaguno SR, Murnan E, Liyanarachchi S, Palanichamy K, Yi JY, Viapiano MS, Nakano I, Yoon SO, Wu H, Parada LF, Kwon CH. 2014. Suppression of peroxiredoxin 4 in glioblastoma cells increases apoptosis and reduces tumor growth. PLoS One 7:e42818.
21. Kim TH, Song J, ParikhParikh AK, Nakano I, Balveen K, Yu Jianhua, Yoon SO, Kwon CH. 2014. Piperlongumine treatment inactivates peroxiredoxin 4, exacerbates endoplasmic reticulum stress, and preferentially kills high-grade glioma cells. Neuro Oncol doi: 10.1093/neuonc/nou088.
22. Kleihues P CW. 2000. Pathology and genetics of tumours of the nervous system. Lyon: IARC Press.
23. Kwon CH, Zhao D, Chen J, Alcantara S, Li Y, Burns DK, Mason RP, Lee EY, Wu H, Parada LF. 2008. Pten haploinsufficiency accelerates formation of high-grade astrocytomas. Cancer Res 68:3286-3294.
24. Lathia JD, Heddleston JM, Venere M, Rich JN. 2011. Deadly teamwork: neural cancer stem cells and the tumor microenvironment. Cell Stem Cell 8:482-485.
25. Lee J, Kotliarova S, Kotliarov Y, Li A, Su Q, Donin NM, Pastorino S, Purow BW, Christopher N, Zhang W, Park JK, Fine HA. 2006. Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell 9:391-403.
26. Li M, Lin YM, Hasegawa S, Shimokawa T, Murata K, Kameyama M, Ishikawa O, Katagiri T, Tsunoda T, Nakamura Y, Furukawa Y. 2004. Genes associated with liver metastasis of colon cancer, identified by genome-wide cDNA microarray. Int J Oncol 24:305-312.
27. Lin CJ, Lee CC, Shih YL, Lin CH, Wang SH, Chen TH, Shih CM. 2012. Inhibition of mitochondria- and endoplasmic reticulum stress-mediated autophagy augments temozolomide-induced apoptosis in glioma cells. PLoS One 7:e38706.
28. Liu H, Luo R, Chen X, Liu J, Bi Y, Zheng L, Wu X. 2013a. Tissue distribution profiles of three antiparkinsonian alkaloids from Piper longum L. in rats determined by liquid chromatography-tandem mass spectrometry. J Chromatogr B Anal Technol Biomed Life Sci 928:78-82.
29. Liu JM, Pan F, Li L, Liu QR, Chen Y, Xiong XX, Cheng K, Yu SB, Shi Z, Yu AC, Chen XQ. 2013b. Piperlongumine selectively kills glioblastoma multiforme cells via reactive oxygen species accumulation dependent JNK and p38 activation. Biochem Biophys Res Commun 437:87-93.
30. Liu X, Zeng B, Ma J, Wan C. 2009. Comparative proteomic analysis of osteosarcoma cell and human primary cultured osteoblastic cell. Cancer Invest 27:345-352.
31. Martin KR, Barrett JC. 2002. Reactive oxygen species as double-edged swords in cellular processes: low-dose cell signaling versus high-dose toxicity. Hum Exp Toxicol 21:71-75.
32. Martinez-Outschoorn UE, Trimmer C, Lin Z, Whitaker-Menezes D, Chiavarina B, Zhou J, Wang C, Pavlides S, Martinez-Cantarin MP, Capozza F, Witkiewicz AK, Flomenberg N, Howell A, Pestell RG, Caro J, Lisanti MP, Sotgia F. 2010. Autophagy in cancer associated fibroblasts promotes tumor cell survival: role of hypoxia, HIF1 induction and NFkappaB activation in the tumor stromal microenvironment. Cell Cycle 9:3515-3533.
33. Miyazaki T, Pan Y, Joshi K, Purohit D, Hu B, Demir H, Mazumder S, Okabe S, Yamori T, Viapiano M, Shin-ya K, Seimiya H, Nakano I. 2012. Telomestatin impairs glioma stem cell survival and growth through the disruption of telomeric G-quadruplex and inhibition of the proto-oncogene, c-Myb. Clin Cancer Res 18:1268-1280.
34. Mohyeldin A, Garzon-Muvdi T, Quinones-Hinojosa A. 2010. Oxygen in stem cell biology: a critical component of the stem cell niche. Cell Stem Cell 7:150-161.
35. Nakano I, Masterman-Smith M, Saigusa K, Paucar AA, Horvath S, Shoemaker L, Watanabe M, Negro A, Bajpai R, Howes A, Lelievre V, Waschek JA, Lazareff JA, Freije WA, Liau LM, Gilbertson RJ, Cloughesy TF, Geschwind DH, Nelson SF, Mischel PS, Terskikh AV, Kornblum HI. 2008. Maternal embryonic leucine zipper kinase is a key regulator of the proliferation of malignant brain tumors, including brain tumor stem cells. J Neurosci Res 86:48-60.
36. Nakano I, Joshi K, Visnyei K, Hu B, Watanabe M, Lam D, Wexler E, Saigusa K, Nakamura Y, Laks DR, Mischel PS, Viapiano M, Kornblum HI. 2011. Siomycin A targets brain tumor stem cells partially through a MELK-mediated pathway. Neuro Oncol 13:622-634.
37. Oliva CR, Moellering DR, Gillespie GY, Griguer CE. 2011. Acquisition of chemoresistance in gliomas is associated with increased mitochondrial coupling and decreased ROS production. PLoS One 6:e24665.
38. Paradies G, Petrosillo G, Pistolese M, Ruggiero FM. 2000. The effect of reactive oxygen species generated from the mitochondrial electron transport chain on the cytochrome c oxidase activity and on the cardiolipin content in bovine heart submitochondrial particles. FEBS Lett 466:323-326.
39. Park HJ, Kim BG, Lee SJ, Heo SH, Kim JY, Kwon TH, Lee EB, Ryoo HM, Cho JY. 2008. Proteomic profiling of endothelial cells in human lung cancer. J Proteome Res 7:1138-1150.
40. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Siu IM, Gallia GL, Olivi A, McLendon R, Rasheed BA, Keir S, Nikolskaya T, Nikolsky Y, Busam DA, Tekleab H, Diaz LA, Jr, Hartigan J, Smith DR, Strausberg RL, Marie SK, Shinjo SM, Yan H, Riggins GJ, Bigner DD, Karchin R, Papadopoulos N, Parmigiani G, Vogelstein B, Velculescu VE, Kinzler KW. 2008. An integrated genomic analysis of human glioblastoma multiforme. Science 321:1807-1812.
41. Pennington JD, Wang TJ, Nguyen P, Sun L, Bisht K, Smart D, Gius D. 2005. Redox-sensitive signaling factors as novel molecular targets for cancer therapy. Drug Resist Update 8:322-330.
42. Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, Wu TD, Misra A, Nigro JM, Colman H, Soroceanu L, Williams PM, Modrusan Z, Feuerstein BG, Aldape K. 2006. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 9:157-173.
43. Prados MD, Russo C. 1998. Chemotherapy of brain tumors. Semin Surg Oncol 14:88-95.
44. Pritchard C, Mecham B, Dumpit R, Coleman I, Bhattacharjee M, Chen Q, Sikes RA, Nelson PS. 2009. Conserved gene expression programs integrate mammalian prostate development and tumorigenesis. Cancer Res 69:1739-1747.
45. Raj L, Ide T, Gurkar AU, Foley M, Schenone M, Li X, Tolliday NJ, Golub TR, Carr SA, Shamji AF, Stern AM, Mandinova A, Schreiber SL, Lee SW. 2011. Selective killing of cancer cells by a small molecule targeting the stress response to ROS. Nature 475:231-234.
46. Santos CX, Tanaka LY, Wosniak J, Laurindo FR. 2009. Mechanisms and implications of reactive oxygen species generation during the unfolded protein response: roles of endoplasmic reticulum oxidoreductases, mitochondrial electron transport, and NADPH oxidase. Antioxid Redox Signal 11:2409-2427.
47. Shi X, Zhang Y, Zheng J, Pan J. 2012. Reactive oxygen species in cancer stem cells. Antioxid Redox Signal 16:1215-1228.
48. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO, European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups, National Cancer Institute of Canada Clinical Trials Group. 2005. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987-996.
49. 2 produced during disulphide formation. J Cell Sci 123:2672-2679.
50. Venere M, Fine HA, Dirks PB, Rich JN. 2011. Cancer stem cells in gliomas: identifying and understanding the apex cell in cancer's hierarchy. Glia 59:1148-1154.
51. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, Alexe G, Lawrence M, O'Kelly M, Tamayo P, Weir BA, Gabriel S, Winckler W, Gupta S, Jakkula L, Feiler HS, Hodgson JG, James CD, Sarkaria JN, Brennan C, Kahn A, Spellman PT, Wilson RK, Speed TP, Gray JW, Meyerson M, Getz G, Perou CM, Hayes DN, Cancer Genome Atlas Research Network. 2010. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17:98-110.
52. Visnyei K, Onodera H, Damoiseaux R, Saigusa K, Petrosyan S, De Vries D, Ferrari D, Saxe J, Panosyan EH, Masterman-Smith M, Mottahedeh J, Bradley KA, Huang J, Sabatti C, Nakano I, Kornblum HI. 2011. A molecular screening approach to identify and characterize inhibitors of glioblastoma stem cells. Mol Cancer Ther 10:1818-1828.
53. Vlashi E, Lagadec C, Vergnes L, Matsutani T, Masui K, Poulou M, Popescu R, Della Donna L, Evers P, Dekmezian C, Reue K, Christofk H, Mischel PS, Pajonk F. 2011. Metabolic state of glioma stem cells and nontumorigenic cells. Proc Natl Acad Sci U S A 108:16062-16067.
54. Wei Q, Jiang H, Xiao Z, Baker A, Young MR, Veenstra TD, Colburn NH. 2011. Sulfiredoxin-Peroxiredoxin IV axis promotes human lung cancer progression through modulation of specific phosphokinase signaling. Proc Natl Acad Sci U S A 108:7004-7009.
55. Wellen KE, Thompson CB. 2010. Cellular metabolic stress: considering how cells respond to nutrient excess. Mol Cell 40:323-332.
56. Yuan Y, Xue X, Guo RB, Sun XL, Hu G. 2012. Resveratrol enhances the antitumor effects of temozolomide in glioblastoma via ROS-dependent AMPK-TSC-mTOR signaling pathway. CNS Neurosci Ther 18:536-546.
57. Zhou BB, Zhang H, Damelin M, Geles KG, Grindley JC, Dirks PB. 2009. Tumour-initiating cells: challenges and opportunities for anticancer drug discovery. Nat Rev Drug Discov 8:806-823.
58. Zito E, Melo EP, Yang Y, Wahlander A, Neubert TA, Ron D. 2010. Oxidative protein folding by an endoplasmic reticulum-localized peroxiredoxin. Mol Cell 40:787-797.